Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]MLN6907 PET Imaging in Metastatic Colorectal Carcinoma
NCT02056015Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Sep 2015
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]MLN6907 in colorectal carcinoma (CRC), sponsored by Millennium Pharmaceuticals. Primary endpoints: Adverse events, serious AEs, clinical laboratory values, and vital signs up to 26 months and Human organ and whole body absorbed dose values at Day 1. Started Jun 2015; status: completed.
02
Drugs
[68Ga]MLN6907
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT02056015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02056015.